UC San Diego Health researchers are helping lead a groundbreaking national study exploring how artificial intelligence (AI) could transform breast cancer screening and improve the patient experience.
Led by UCLA and UC Davis, the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) is the first large-scale, randomized clinical trial in the U.S. to evaluate AI’s role in mammogram interpretation. Supported by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI), the multi-institutional study brings together seven leading academic medical centers, including UC San Diego Health, to determine whether AI can help radiologists detect breast cancer more accurately while reducing unnecessary callbacks and anxiety for patients.
Leading the effort at UC San Diego Health are Haydee Ojeda-Fournier, MD and Professor of Radiology and site principal investigator, and Tara Retson, MD and Assistant Professor of Radiology and co-principal investigator. Both are also faculty affiliates at the Jacobs Center for Health Innovation (JCHI).
“This is an unprecedented opportunity to understand how AI may complement expert breast radiologists,” Dr. Ojeda-Fournier says. “Despite the enthusiasm for AI, we truly don’t yet know if it works in real-life clinical settings. PRISM will help us find out.”
The study uses Transpara Breast AI by ScreenPoint Medical, integrated into clinical workflows through the Aidoc aiOS platform. While AI assists in image interpretation, every mammogram in the trial is still read and finalized by a radiologist, ensuring that patient care remains guided by clinical expertise.